MC-VA-PABC-MMAE

• UNSPSC Description:

  MC-VA-PABC-MMAE is a agent-linker conjugate for ADC. MC-VA-PABC-MMAE contains the ADCs linker (peptide MC-VA-PABC) and a potent tubulin polymerization inhibitor MMAE (HY-15162)[1][2].

• Target Antigen:

  Drug-Linker Conjugates for ADC

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/mc-va-pabc-mmae.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  C[C@@H](C(N[C@H](C)[C@H](C1=CC=CC=C1)O)=O)[C@H]([C@@](CCC2)([H])N2C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(OCC(C=C3)=CC=C3NC([C@H](C)NC([C@H](C(C)C)NC(CCCCCN(C4=O)C(C=C4)=O)=O)=O)=O)=O)=O)=O)=O)OC

• Molecular Weight:

  1230.53

• References & Citations:

  [1]Wang Y, et al. Development of applicable thiol-linked antibody-drug conjugates with improved stability and therapeutic index. Drug Deliv. 2022 Dec;29(1):754-766.|[2]Cazzamalli S, et al. Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma. J Control Release. 2017 Jan 28;246:39-45.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  No Development Reported

• CAS Number:

  1818864-51-5